BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy
SALT LAKE CITY, February 9, 2010-BSD Medical Corporation (NASDAQ:BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1 surgical resection of their tumor (complete removal or only microscopic tumor remaining). The coordinating investigator is Rolf D. Issels, MD PhD, Department of Medical Oncology, Klinikum Grosshadern, Munich University Medical School, Munich, Germany. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.
The Phase III study was initiated following completion of a Phase II study that utilized chemotherapy and hyperthermia to treat 21 inoperable pancreatic patients who were resistant to or had failed previous chemotherapy gemcitabine treatments, a patient population with a dire prognosis. There was one complete response (complete disappearance of the tumor), 3 partial responses (more than 50% tumor reduction), and 7 patients with stable disease (no tumor growth). The study results demonstrated a low toxicity rate and an overall survival of 16.9 months. By comparison, the median survival for inoperable pancreatic cancer patients after gemcitabine treatment is only 6 months. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.
To view complete press release, please visit: http://bsdmedical.com/press_view.php?press_id=322
BSD Medical Corporation
If this company were making a profit, it would be a $10 stock!
The only reason it has not been making a profit is that it's been a one product company. As of today, it is now a 2 product company. As it's already been pointed out, this second product has a very nice potential consumables business - that makes today's approval significant as sales/revenues will be expected to grow dramatically. They also have a 3rd product which could be approved any day now, and that will move this up further.
My view is that this is will be a $5 stock in the short term. I believe they have a backlog of sales that are pending this approval, and that will show up in the next 2 quarterly's - sales results will move this stock to $10 in 6-9 months. It could go further from there, on these two products alone - but - if the BSD2000 is approved (the 3rd product)the stock will go up another $5-$10/share on that news alone.
I would not be penny wise and pound foolish at this time. Trying to buy $.10 below some arbitrary price will potentially cost you dollars over the next year.
By the way, I've owned this stock for many years. I'm happy about today - and I knew this day would come. I'm a holder not a trader, so I don't get too spun up (or down) about this stuff. I am very confident that over the next few years, I will make a bunch on this one - thus, I could care less what happens tomorrow.
That's my view.
sarcasm....I'm not allowed to buy in when there seemed to be growing interest after several months of slow bleeding, according to some. Since I am in above the current level but certainly far off of the $2.75 high of last week, I am a bagholder. My bag holds a mere 6500 shells. I'll consider more in the next two or three months.